Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News for 'CEXI' - (Brigham and Women's Hospital Selects ValiMed(TM) by CDEX as Part of Its Medication Safety Program)
TUCSON, AZ, Sep 01, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces that Brigham and Women's Hospital (Boston, MA) has
selected the CDEX ValiMed(TM) Medication Safety System as part of its Medication
Safety Program. Studies worldwide continue to show that mistakes in the
compounding of high-risk medications occur and result in substantial harm to
patients and economic loss to hospitals. In an 18-month University of Michigan
Health System study, ValiMed identified 5 major medical errors (see
http://www.ns.umich.edu/htdocs/releases/story.php?id=6255). ValiMed is used to
validate the compounding of high-risk liquid medications in a pharmacy setting
and also as a verification program to reduce the diversion of return narcotics
in hospitals and other healthcare facilities.
"We selected two ValiMed units to provide additional assurance of accuracy for
our robotic compounding and to validate the return of narcotics," said William
Churchill, Executive Director of Pharmacy. "Assuring the safety of our patients
is job one at Brigham and ValiMed will help with that goal."
"Brigham and Women's Hospital joins the list of other world class hospitals that
have selected ValiMed as part of their Medication Safety Program and we look
forward to working with Bill and his staff to integrate ValiMed into their daily
practices," said Greg Firmbach, CDEX Senior Vice President.
News for 'CEXI' - (Hospitals Order Multiple ValiMed Units to Enhance Patient Safety and Reduce Narcotic Diversion; CDEX Signs Its First Pay-Per-Use Agreement)
TUCSON, AZ, Aug 26, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces the signing of two multi-unit contracts for the
placement of four new ValiMed Units in U.S. hospitals. One of the contracts was
for the direct purchase of two units and one contract was a two unit Pay-Per-Use
pricing plan that CDEX recently implemented to allow more hospitals to afford
this life saving medication safety technology. ValiMed is used to validate "The
Right Drug at The Right Dose" when high-risk liquid medications are compounded
in a pharmacy setting and also as a verification program to reduce the diversion
of return narcotics in hospitals and other healthcare facilities.
"The signing of our first Pay-Per-Use Agreement for multiple units marks the
beginning of a new era that puts ValiMed in reach of every hospital no matter
size or specialty," said Greg Firmbach, Senior Vice President of CDEX.
"Pay-Per-Use pricing is an all inclusive turnkey approach to placing this
life-saving technology with equipment, supplies and service all for $2.50 per
test or less from the hospitals operating (not capital) budgets. We have brought
in another sales consultant to accommodate the growing interest and enthusiasm
in the marketplace for this innovative pricing model."
This is not a re-post board for Raging Bull! Please read the rules of the board. You are getting carried away with Raging Bull posts again. Are you that bored that you have to go over there for material. Aren't you tired of repeating your selves yet?
News for 'CEXI' - (CDEX Inc. Announces Change in Board of Directors)
TUCSON, AZ, Jun 24, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announces the resignation of General Robert H. Foglesong, U.S. Air Force
(Retired), from its Board of Directors, effective June 24, 2009. General
Foglesong (ret) has served on the Board of Directors since May 2008 and resigns
in order to spend more time dealing with issues critical to his family.
"I regret having to leave the Board at this time, but my personal family
situation dictates my resignation from a number of Boards that I was serving
on," said General Foglesong (ret). "I continue to be excited about the CDEX
technology and its applications to patient safety and law enforcement. I wish
Malcolm and the company every success going forward."
"I am disappointed to see General Foglesong leave the CDEX Board but I
understand his reasons. As a Board member he has challenged executive management
in both business and technical directions," said Malcolm Philips, CDEX Chairman.
"General Foglesong leaves the Board and this Company better by his presence and
involvement. We wish him well in the future and look forward to tapping into his
advice periodically as we go forward."
I agree! I was one of those, but not anymore! Somebody had to draw a line in the sand! I guess Milchip is doing it legally. Good for him! MP just can't be getting a free pass anymore. Ineptness does not qualify him to be a CEO of anything! If he was out in the real world, he would have been fired long ago!
Mike, I hope that is the true situation! That Cdex is in production, and the orders are rolling in. I want it for the shareholders.
CDEX does owe an explanation to it's public. MP is afraid of his own shadow however. CDEX should have come out with something right away. The stumble bum MP can't get out of his own way. Unless it is to hold a prayer meeting?
My question is: Is MP living up to his fiduciary duties?
I know he is doing what is good for him, his family, and friends, but what about the shareholders? If whatever goes around comes around, then he is in for it bigtime!
News for 'CEXI' - (CDEX CEO Provides an Updated Management Briefing; Dr. Wade Poteet Transitions From Principal Scientist to Project Consultant)
TUCSON, AZ, Mar 23, 2009 (MARKET WIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announces that effective April 1, 2009, Dr. Wade Poteet will step down from his
position as Principal Scientist and become a project consultant supporting CDEX
on an as needed basis. Dr. Poteet, the Company's 1QFY0910Q and other subjects
are discussed by CEO Malcolm Philips in the "CEO Corner" of our website at
www.cdexinc.com.
"As CDEX overcame the scientific hurdles associated with our product lines, two
years ago we agreed that I would transition to a support role for the company
allowing me more time to pursue other interests," said Dr. Wade Poteet. "In
January 2008 I started the transition by reducing my work schedule and, after
passing my 65th birthday, will now complete the transition by going to a project
based consulting role with the company. I am very proud of the progress of the
entire CDEX Team over the past seven years in taking a technology from a dream
to where we have two very good product lines making differences in peoples'
lives today. Those at CDEX are very much like family and I wish them well in the
future."
"Dr. Poteet is one of the founding leaders of CDEX," said Malcolm Philips,
founding CDEX CEO. "He has been very instrumental in moving the CDEX technology
to a mature science that forms the basis for expansion of our current product
lines and development of new applications. Wade combines a strong scientific
mind with practical hands-on development, and is rounded out by his outside
interests, including being a grandfather, rancher, member of his Church Choir,
bible study leader and musician who has played over 2820 gigs in the Tucson
area. It is that unique and humble personality that will be sorely missed in the
office. We wish Wade well and know that we will continue to see him frequently."
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare
and security markets. The ValiMed(TM) product line provides life-saving
validation of high-risk medications and returned narcotics. The ID2(TM) product
line detects trace amounts of illegal drugs, such as methamphetamine. CDEX
expects to advance its patented technologies to serve additional markets. To
meet its plans, CDEX must strengthen its financial position as stated
periodically in its SEC filings. For more information, contact Malcolm Philips
at mphilips@cdex-inc.com.
News for 'CEXI' - (CDEX ID2 Meth Scanner(TM) Sold by Decatur Electronics Assists Law Enforcement in Methamphetamine Busts ID2 Meth Scanner Used by Law Enforcement Agencies in a Growing Number of States to Combat the Spread of Methamphetamine)
TUCSON, AZ, Mar 20, 2009 (MARKET WIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announced today that the ID2 Meth Scanner sold by Decatur Electronics
(http://www.decaturradar.com) has been used to fight the war against
methamphetamine in a growing number of jurisdictions including Arizona,
California, Tennessee and Iowa. The ID2 Meth Scanner is a handheld,
battery-operated device that detects trace quantities of methamphetamine while
in the scan mode.
"Since debuting at the October 2008 COPS West Tradeshow, the ID2 Meth Scanner
has been involved with a growing number of law enforcement busts," said Tim
Shriver, Jr., CDEX Security Division Sales Manager. "The most recent involved a
traffic stop where the driver had two bags of white substance, only one of which
the Meth Scanner identified as methamphetamine. Upon further analysis, the
Scanner had correctly identified the meth and correctly rejected the second bag
which was a cutting agent to be used in conjunction with sale of the meth. This
is typical of the reports that we are receiving regarding this initial phase of
Meth Scanner use by police in the field. We are excited by the results and the
growing interest in the ID2 Meth Scanner."
For more information regarding the ID2 Meth Scanner, please visit
http://www.decaturradar.com/decatur/news_profile.php?id=55.
The same old lame old!
MP Sales and A Promotion Company Please.
Merry Christmas and Happy Holidays to all on this board. May this drama end sometime in the near (don't laugh) future. I cannot believe how long we have all been involved in this bad dream. I hope that is has a happy ending which means what? Getting out with your shirt on! Getting out with a profit! Getting out with a tax loss! Not having to read the message board or boards! The time wasted can never be recovered.
Thanks Arloco for the information on sticky notes.
Merry Christmas to all!
PS: Let the oil companies who have held down gas mileage, pay for the automobile company bailouts! Also tell the UAW that their workers are getting paid to much. Example: I believe that a so called tech, is making over $75.00's per hour to put tires on a car? No wonder they can't make any money.
Hello board. I am again falsly accussed of zapping posts. The administration did Coqy! I haven't checked this board in a few days, as I am working very long hours. Thank you your patience.
StandoutStocks.com: "Stocks that Standout" picks for today are: CEXI, PLTG, SHRPQ,
Oct 14, 2008 -- CDEX Inc. (OTCBB: CEXI | Quote | Chart | News | PowerRating) today announced the introduction of its latest product, the ID2 Narcolyzer(TM), at the COPSWEST Trade Show and Conference, recently held in Ontario, California. The ID2 Narcolyzer was featured at the CDEX display booth along with its sister product, the hand-held ID2 Meth Scanner(TM), showcasing CDEX's breakthrough technology for the law enforcement market. The Narcolyzer is an economical, table-top device which employs the same technology used in the CDEX ValiMed CCT system, currently installed at hospitals around the world. The ID2 Narcolyzer identifies illegal drugs within seconds using CDEX's patented enhanced photoemission spectroscopy. The unit will currently identify methamphetamine, cocaine, and heroin, and additional substances will be added based on market demand.
Steve Schmidt, VP of CDEX's Security Division, remarked, "The COPSWEST Show was a great success for CDEX. This prestigious conference featured over 300 exhibitors, a robust educational program and it attracted over 2,000 law enforcement officials eager to see the latest products and technology. We were the only exhibitor featuring illicit drug detection equipment and our booth was very busy from the opening until the closing bell. As we have seen at other demonstrations of our technology, there was fascination and interest for both of our featured products at the booth. The Meth Scanner provides a unique, reliable, and lightweight field instrument and the Narcolyzer is a fast, accurate, in-station device that can be purchased well below the price of conventional analytical equipment."
Mr. Schmidt went on to say, "The overwhelmingly positive responses at COPSWEST validated the efficacy of our technology for law enforcement applications. The products performed flawlessly. Based on the success of its public debut, we will now proceed to a formal launch process for the Narcolyzer and continued market development for the Meth Scanner. The introduction of a second product will build brand awareness for CDEX's ID2 family of illicit drug detectors and attract new distributors to drive increasing revenue streams going forward. We are very excited about our future as a supplier of unique products to help law enforcement in the battle against illegal drugs."
ABOUT CDEX
CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets The Valimed(TM) product line provides life-saving validation of high-risk medications and returned narcotics. The ID2(TM) product line provides revolutionary new tools in the global battle against illegal drugs, such as methamphetamine. CDEX expects to advance its proprietary technology to serve additional markets and applications. Corporate headquarters and R&D facilities are located in Tucson, Arizona, with an international office in Paris, France.
News for 'CEXI' - (CDEX Inc. CEO Concludes Successful European Tour of ValiMed(TM) Distributors and Partnering Hospitals ValiMed(TM) International Expansion is Moving Forward on All Planned Fronts)
TUCSON, Ariz., Oct 13, 2008 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announces that last week CEO Malcolm Philips and Pascal Pouligny, VP of its
Medication Safety Division, met with European distributors to build upon the
progress of its international expansion of ValiMed(TM). The CDEX delegation
toured European hospitals in the United Kingdom, France and Spain, where
interviews were held with hospital officials to discuss customized
specifications for the Company's medication safety products. Philips and
Pouligny concluded that "our international expansion plans are moving forward on
all fronts, with more details to follow in the coming weeks." (For additional
discussion see Mr. Philips' CEO Corner on the Investor Page of the CDEX Web
Site, www.cdexinc.com.)
Philips and Pouligny met with business partner GRIFOLS International SA (BMAD:
GRF) and senior managers at the Vall D'Hebron Hospital in Barcelona, Spain.
GRIFOLS, a global provider of healthcare products and services, is the exclusive
distributor of ValiMed in Spain, Portugal and Italy. "ValiMed is an ideal
extension of the products and services we offer," said Xavier Guix, Marketing
Director at Grifols. "We are pleased with our strong strategic association with
CDEX, and look forward to expanding that relationship in the future."
In France, following up on the recent introduction of ValiMed at the Syndicat
National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers
Universitaires Annual Meeting in Toulouse, Philips and Pouligny held discussions
with Laurent Skvortzoff and Jean-Batiste Guillot, executives at EURAF, exclusive
distributor of ValiMed in France. Together they met with senior management at
major hospitals in Paris. Concluding the European tour, Philips met with senior
management at the Charing Cross, Hammersmith and St. Mary's hospitals in London.
"Our European tour strengthened existing business relationships while laying the
foundations for new ones," Philips remarked. "CDEX currently is represented by
highly regarded distributors in European and Middle Eastern countries, with the
objective of advancing an authoritative presence in all major markets in these
regions. We are selling ValiMed units and supplies into the domestic US and
international markets. With momentum increasing, we believe ValiMed will become
the standard of care for medication safety that will accelerate our movement
into markets around the world. We are continuing to expand our business
alliances toward that goal."
ValiMed(TM) improves patient safety by reducing medication errors, eliminating
harmful counterfeits, identifying narcotic diversion and training compounding
medical personnel. Within seconds ValiMed analyzes a medication's spectroscopic
signature and concentration and returns a quantitative answer requiring no user
interpretation.
ABOUT CDEX
CDEX is a technology development company, currently manufacturing and globally
distributing chemical detection products in the medication safety and security
markets. The ValiMed(TM) product line provides life-saving validation of
high-risk medications and returned narcotics. The ID2(TM) product line is a
revolutionary new tool in the global battle against abuse of illegal drugs such
as methamphetamine. CDEX expects to advance its patented technologies to serve
additional markets and applications. For more information, visit www.cdexinc.com
or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at
(605) 399-3617.
Pinnacle Digest: Announcement From CDEX Inc Makes It A Company Of Interest For Pinnacle Digest
Tue. October 07, 2008; Posted: 03:56 AM
Today’s top stocks. Click here
Oct 07, 2008 (M2 PRESSWIRE via COMTEX) -- CEXI | Quote | Chart | News | PowerRating -- www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from CDEX Inc. (OTCBB:CEXI) announcing a definitive agreement with ACE Trading Company Limited to be a distributor for the CDEX ID2 Meth ScannerTM, our team has launched their exclusive investor controlled forum. Our staff and members have requested that all CDEX shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Once a member of PinnacleDigest.com you will have access to all our CDEX research. It is our goal to find viable opportunities for each one of our members.
Join PinnacleDigest.com to
Find out if CDEX makes it as a Pinnacle Featured Company
Chat with other shareholders invested in CDEX
Explain to our investor community what differentiates this company
Connect with investors and professionals in the equity markets
Meet the thousands of investors who have already become members of the Pinnacle community.
PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.
PinnacleDigest.com has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.
All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.
CONTACT: Pinnacle Digest WWW: http://www.PinnacleDigest.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
For full details for CEXI click here.
News for 'CEXI' - (CDEX Inc. Security Division Announces First Shipment to New Distributor in Japan)
TUCSON, Ariz., Oct 06, 2008 (BUSINESS WIRE) -- CDEX Inc. (OTCBB:CEXI) today
announced a definitive agreement with ACE Trading Company Limited to be a
distributor for the CDEX ID2 Meth Scanner(TM). Ace Trading, based in Tokyo will
distribute the Scanner to law enforcement, customs facilities, schools, home
inspection and other markets throughout Japan where methamphetamine detection is
critical.
Steve Schmidt, VP of CDEX's Security Division noted, "The use of methamphetamine
has increased dramatically in Japan in recent years. There are an estimated 1-2
million users and Meth is the most widely used illegal drug in the country. The
ID2 Meth Scanner(TM) is an important, new, front-line tool in the battle against
methamphetamine manufacturing and use and the subsequent adverse public safety
and health effects associated with passive exposure to the precursor chemicals
and residual drug product."
Mr. Schmidt went on to say, "We are very excited to have Ace Trading Company as
part of our global distribution network. ACE is a major player in the Japanese
marketplace, with extensive business relationships across the country. Mr. Goro
Adachi, CEO of ACE Trading, was for many years an executive of one of the
world's largest trading companies. ACE works closely with many of the largest
Japanese trading companies. CDEX's strategy to develop a comprehensive global
distribution network is being realized and establishing a significant presence
in Japan is an important step forward. This increasing network of marketing
representatives enables CDEX to expand sales going forward. We will continue to
identify, qualify and sign distributors in the North American market and in
selected international markets where methamphetamine abuse is taking a toll on
human societies."
ABOUT CDEX
CDEX is a technology development company, currently manufacturing and globally
distributing advanced chemical detection products, based on its patented
Enhanced Photoemission Spectroscopy technology. Currently CDEX is organized to
serve two critical markets -- Medication Safety and Security. The Valimed
System(TM) product line is providing life-saving validation of high-risk
medications and returned narcotics in healthcare facilities and pharmacies. The
ID2 Meth Scanner(TM) product line is a revolutionary new tool in the global
battle against the growingpublic safety threat of methamphetamine abuse and its
toxic impact on the general public. Both of these product lines substantiate the
superiority of our technology and also demonstrate the accuracy, reliability,
speed and ease of use. CDEX expects to advance its proprietary technology to
serve additional markets and applications. Corporate headquarters and R&D
facilities are located in Tucson, Arizona with an international office in Paris,
France.
CDEX Reports Progress through Q3 FY 2008
Revenues to Date "Surpass Revenues" for FY 2007, ID2 Meth Scanner(TM) Ships, Global Acceptance of ValiMed "Increases"!
Last update: 9:33 a.m. EDT Sept. 19, 2008
TUCSON, Ariz., Sep 19, 2008 (BUSINESS WIRE) -- With the filing of its 3Q FY08 Financial Report on Form 10-QSB, CDEX Inc.
10:31am 09/19/2008
CEXI 0.25, 0.00, 0.0%) announced revenues for the first nine months of FY08 that surpassed revenues for the entire FY2007. Revenues for the third quarter of FY2008 reported on the Form 10-QSB did not reflect international shipments of the ValiMed(TM) Model CCT because of a delay in receiving the TUV approval which, as previously announced, was granted with resulting international shipments of the ValiMed Model CCT in the 4th quarter. Accordingly, while year-to-date revenues for FY2008 exceeded revenues for all of FY2007, the 3rd quarter revenues were lower than expected. (The Form 10 QSB is accessible at www.cdexinc.com.)
"The third quarter saw a number of milestone achievements in CDEX's march to growth and profitability," said Malcolm Philips, CDEX CEO and chairman. "We have expanded our customer base for ValiMed in the United States and continued to grow the distribution channel internationally. Significantly, we have expanded our ValiMed Medication Signature Library to include heparin, which as widely reported has been involved in several recent tragic incidents. In addition, we sold and shipped the first units of our new product line, the ID2 Meth Scanner, and signed our first national and international Meth Scanner distributors. I should add that both the Meth Scanner and ValiMed product lines rely on the same patented technology, which gives the company leverage as we expand into new markets," continued Mr. Philips. "With the launch of the Meth Scanner and the increasing market acceptance of ValiMed, we fully expect FY 2009 to be another year of record revenue, significantly surpassing FY 2008." For more information on Mr. Philips' assessment of the third quarter, visit the CEO Corner in the Investor Section of the CDEX Web site ( www.cdexinc.com).
Pinnacle Digest: CDEX Inc. Announcement Attacts Interest Of Leading Online Investment Group
Sep 16, 2008 (M2 PRESSWIRE via COMTEX) --
Company: Cdex Inc (CEXI)
www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from CDEX Inc. (OTCBB: CEXI) announcing that its new ValiMed Model CCT has successful completed certification testing and TUV Rheinland of North American Inc. has authorized use of the TUV mark, our team has launched their exclusive investor controlled forum. Our staff and members have requested that all CDEX Inc. shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Once a member of PinnacleDigest.com you will have access to all our CDEX Inc. research. It is our goal to find viable opportunities for each one of our members.
Join PinnacleDigest.com to
Find out if CDEX Inc. makes it as a Pinnacle Featured Company
Chat with other shareholders invested in CDEX Inc.
Explain to our investor community what differentiates this company
Connect with investors and professionals in the equity markets
Meet the thousands of investors who have already become members of the Pinnacle community.
PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.
PinnacleDigest.com has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
Sorry girls and boys that don't own CDEX stock, I don't buy your agenda. Too bad if you don't like my opinion. I could care less what you think. CDEX will make it despite that you have been posting for how many years? With your un-clever remarks. Talk about wasting ones time! I am wasting mine right now posting to you.
Amazing non-shareholders so concerned about a quarterly report! Beyond amazing and interesting that they would have so much concern, after so many years? It sure raises some questions. Go CDEX!
TODAYS PRESS RELEASES
September 15, 2008 — ValiMed™ Model CCT Receives Clean Bill of Health from TUV Rheinland of North America, Inc.; CDEX is Authorized to use TUV Mark
Completion of certification testing provides avenues for expanded global markets for the new ValiMed™ Model CCT.
Tucson, Arizona – September 15, 2008 – Following recent announcements concerning reference testing of ValiMed™ Units at international flagship hospitals, CDEX Inc. (OTCBB: CEXI) announces that its new ValiMed Model CCT has successful completed certification testing and TUV Rheinland of North American Inc. (www.us.tuv.com) has authorized use of the TUV mark. The testing and evaluations were conducted in conjunction with Elliot Laboratories (www.elliotlabs.com) for compliance with Electromagnetic Testing for Electrical Equipment for Measurement, Control and Laboratory Use.
CCTThe new ValiMed™ Medication Validation and Narcotics Return System (Model CCT), introduced first to the international market, is a light-weight, compact, table top instrument that can be used in virtually any clinical environment where high-risk IV medications are compounded before being dispensed to the patient or where narcotics are returned after being used.
“The award of the TUV mark reflects completion of exhaustive testing of the new ValiMed Model and dedication of the CDEX Team that developed it,” said Carlos Alvarez, VP of CDEX’s Technical Operations Division. “The evaluation and testing was conducted to the same requirements and standards utilized by UL for the U.S. market, ULC for the Canadian market, CE for the European Union market, and CB Scheme for other international markets. In addition, in our design of the CCT Model we assured that it only contained RoHS compliant components, a step forward for the international marketplace.”
“The award of the TUV mark is another major milestone in the manufacturing and marketing of the CCT,” said Tim Shriver, CDEX COO. “This step was crucial in expanding our distributor base to other countries and providing a global product that will improve medication safety throughout the world.”
(CDEX Inc. Launches New Web Site New CDEX Web Site Contains Updated Information Concerning the Company and Its ValiMed(TM) and ID2 Meth Scanner Product Lines for Clients, Shareholders and Distribution Partners)
THIS IS A REALLY IMPROVED WEBSITE! http://cdexinc.com/
TUCSON, Ariz., Sep 10, 2008 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announces the launch of its redesigned and updated corporate web site,
www.CDEXInc.com. The new site provides customers, investors and the general
public a comprehensive source for important information about the company, its
products and its mission. It features in-depth presentations of the history,
technology and people that make CDEX a fast-growing and exciting global
technology development company. It provides extensive insight into the company's
two product lines, ValiMed(TM) (validating high-risk medications and narcotics
for the health care markets) and the ID2 Meth Scanner(TM) (detecting trace
quantities of methamphetamine on virtually all surfaces in a scan mode). The
site features Resource Centers with many useful downloads and links and contains
a robust Investor Information section to keep existing and potential investors
informed and up-to-date. Customers may also purchase products using the Shopping
Cart function.
"Redesign and deployment of the new web site was truly a dynamic team effort,"
said Steve Schmidt, CDEX VP and GM of the Security Division who led the Web Site
Redesign Project. "We assembled a great creative team of Karen Scott, owner of
Gr8Scott Design, Ildiko Palyka, owner of Ildiko Designs, and Robin Mangan, copy
writer. We then involved the entire CDEX team in the project." He went on to
say, "In many ways, corporate web sites are the face of business in today's
global economy. We are very pleased to now have a web site where form and
function combines to more fully portray the dynamic nature of our technology,
our company capabilities and our mission of providing innovative solutions in an
unsafe world. We look forward to the daily challenge to improve and update the
site and welcome feedback from our visitors."
ABOUT CDEX
CDEX is a technology development company, currently manufacturing and globally
distributing advanced chemical detection products, based on its patented
Enhanced Photoemission Spectroscopy technology. The company provides unique
solutions to the challenges of identifying substances in difficult to monitor
environments. CDEX technology is being adapted to market needs for medication
validation, hazardous chemicals detection, and brand protection through analysis
of counterfeit substances. CDEX is organized to serve two critical markets --
Medication Safety and Security. The Valimed(TM) System is providing life-saving
validation of high-risk medications and narcotics in healthcare facilities and
pharmacies around the world. The ID2 Meth Scanner(TM) is a revolutionary new
tool in the global battle against the growing scourge of methamphetamine abuse
and its toxic impact on the general public. Corporate headquarters and R&D
facilities are located in Tucson, Arizona, with international offices in Paris,
France. For more information, visit www.CDEXInc.com and www.valimed.com or
contact Steve Schmidt (sschmidt@cdex-inc.com) at (520) 745-5172 x212.
New PR on the CDEX website:
http://www.cdexinc.net/
September 9, 2008 — ValiMed™ Reduces Drug Diversion in Hospitals Quickly and Inexpensively
Nursing Journal Discusses Benefits of CDEX’s ValiMed™ Technology in the Monitoring of Narcotic Returns in the Operating Suite
Tucson, Arizona - September 9, 2008 – CDEX Inc. (OTCBB: CEXI). CDEX Inc. (OTCBB: CEXI). An article published in the August issue of the Association of Perioperative Registered Nurses (AORN) Journal documents the benefits of CDEX ‘s Enhanced Photoemission Spectroscopy Technology in reducing narcotics diversion in the healthcare community. AORN J 88 (August 2008) 249–252. © AORN, Inc, 2008. http://www.aornjournal.org/article/S0001-2092(08)00258-5/abstract. The AORN Journal publication conclusion is similar to an earlier American Journal of Health-System Pharmacists peer reviewed article detailing an 18 month independent study of the ValiMed™ Medication Validation System. Am J Health-Syst Pharm--Vol 65, pp 49-54, Jan 1, 2008.
“Drug diversion is an ongoing problem in health care settings,” said Dr. Kevin B. Sharer, MD, MBA, CPE and author of the publication. “Records of the flow of controlled substances are kept by various accounting systems, but these systems can be inaccurate because the returned medications rarely are tested to verify that they have not been diluted or replaced. For example, fentanyl is a potent narcotic that is administered frequently in hospitals for the relief of pain as an adjunct to anesthesia in surgical procedures. It is diverted primarily from operating rooms through product substitution or outright theft, resulting in the potential under dosing of patients and falsifying of records,” continued Dr. Sharer. “The ValiMed System technology provides a quick and relatively inexpensive solution to this problem.”
The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures such as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
News for 'CEXI' - ([video] Malcolm Philips, CEO of CDEX, Inc. Discusses First Shipments of ValiMed(TM) Model CCT System to International Customers on WallSt.net's 3-Minute Press Show)
TUCSON, Ariz., Aug 25, 2008 /PRNewswire-FirstCall via COMTEX/ -- CDEX, Inc.
(OTC Bulletin Board: CEXI), a technology development company, today announced
that the company's CEO, Malcolm Philips, is featured in an exclusive interview
on WallSt.net's 3-Minute Press Show.
The interview gives viewers an overview of the company, and the significance of
the company's latest press release.
To view the clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Malcolm-Philips-CEXI/218/921
News for 'CEXI' - (Malcolm Philips, CEO of CDEX Inc., Discusses Recent Expansion of ValiMed(TM) and ID2 Meth Scanner(TM) Markets in an Exclusive Interview on WallSt.net's 3-Minute Press Show)
NEW YORK and TUCSON, Ariz., July 21, 2008 /PRNewswire-FirstCall via COMTEX/ --
CDEX Inc. (OTC Bulletin Board: CEXI), a technology development company,
currently manufacturing and globally distributing advanced chemical detection
products, based on its patented Enhanced Photoemission Spectroscopy technology,
today announced that Malcolm Philips, the company's President and CEO, is
featured in an exclusive interview on WallSt.net's 3-Minute Press Show to
discuss recent press releases related to its two product lines, ValiMed(TM) and
the ID2 Meth Scanner(TM).
To view the clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/malcolm-philips cexi/167/741
About CDEX Inc.
CDEX is a technology development company, currently manufacturing and globally
distributing advanced chemical detection products, based on its patented
Enhanced Photoemission Spectroscopy technology. With this technology, the
company is providing unique solutions to the challenges of identifying
substances in difficult to monitor environments. CDEX technology is being
adapted to market needs for medication validation, hazardous chemicals
detection, and brand protection through analysis of counterfeit substances.
Currently, CDEX is organized to serve the two critical markets encompassing our
existing product lines -- Medication Safety and Security. The Valimed(TM) System
product line is providing life-saving validation of high-risk medications and
return narcotics in healthcare facilities and pharmacies. The ID2 Meth
Scanner(TM) product line is a revolutionary new tool in the global battle
against the growing scourge of methamphetamine abuse and its toxic impact on the
general public. Corporate headquarters and R&D facilities are located in Tucson,
Arizona with an international office in Paris, France. For more information,
visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate
Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212
CDEX Announces First Sales and Deliveries of ID2 Meth Scanner(TM) CDEX Sells and Delivers ID2 Meth Scanners(TM) for Methamphetamine Detection to U.S. Clients in the Law Enforcement and Home Inspection Markets, and to U.S. and International Distributors)
TUCSON, AZ, Jul 17, 2008 (MARKET WIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announces its first sales and deliveries of ID2 Meth Scanners(TM) for
methamphetamine detection to U.S. clients in the Law Enforcement and Home
Inspection Markets, and to U.S. and international distributors. The ID2 Meth
Scanner(TM) is a hand-held, battery operated device that detects trace amounts
of methamphetamine (low nanogram range) on virtually any surface while in the
continuous scan mode. It employs the same CDEX patented Enhanced Photoemission
Spectroscopy technology used in the ValiMed(TM) System, currently saving lives
in hospitals today.
"We are excited about the commercialization of the ID2 Meth Scanner following
two years of extensive R&D, beta testing and market research by the CDEX Team,"
said Steve Schmidt, VP and General Manager of CDEX's Security Division. The
scourge of methamphetamine abuse is growing exponentially around the world. It
is estimated that over 13 million are addicted to methamphetamine in the U.S.
alone, raising significant concerns of officials in law enforcement, homeland
security, school systems and the border patrol, as well as the unsuspecting
consumers purchasing homes and used automobiles. "Residue from use or production
of methamphetamine in homes, schools, automobiles, hotels and public buildings
raises serious health risks for those exposed," Schmidt continued. "CDEX plans
to build an extensive distribution network around the world, particularly in
countries where meth abuse, manufacturing or distribution is at dangerous
levels. This marks the first step in that process."
About CDEX Inc.
CDEX is a technology development company, currently manufacturing and globally
distributing advanced chemical detection products, based on its patented
Enhanced Photoemission Spectroscopy technology. With this technology, the
company is providing unique solutions to the challenges of identifying
substances in difficult to monitor environments. CDEX technology is being
adapted to market needs for medication validation, hazardous chemicals
detection, and brand protection through analysis of counterfeit substances.
Currently, CDEX is organized to serve the two critical markets encompassing our
existing product lines -- Medication Safety and Security. The Valimed(TM) System
product line is providing life-saving validation of high-risk medications and
return narcotics in healthcare facilities and pharmacies. The ID2 Meth
Scanner(TM) product line is a revolutionary new tool in the global battle
against the growing scourge of methamphetamine abuse and its toxic impact on the
general public. Corporate headquarters and R&D facilities are located in Tucson,
Arizona with an international office in Paris, France. For more information,
visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate
Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.
CDEX Files Its 2Q FY08 Financial Report, 10QSB, Which Reflects a Continuing Trend of Significantly Increasing Revenue, Year Over Year!
No matter what the non shareholders say, this is a good sign.
Go CDEX! Sorry I have been gone for sometime now, business in Wyoming. It appears that CDEX is headed in a successful direction. A thumbs up to the company and it's loyal shareholders. To the naysayers, I hope your past catches up with you.
Thank you Paige. First of all "the shareholders" on this message board appreciate that you went to the shareholders meeting. Secondly that you took the time to share your thoughts with us. Thank you.
I believe that CDEX is going forward, and will be successful.
Paige could you please tell us what you heard and witnessed, at the shareholders meeting? Thank you.
(CDEX Announces Record Quarter in ValiMed(TM) Sales/Leases; CDEX on Pace for Another Record Year in Revenues CDEX CEO Malcolm Philips Will Appear on The 3 Minute Press Show on www.WallSt.net on Monday, April 14, 2008 (http://tv.wallst.net/3-min-press/3-min-press.php))
TUCSON, AZ, Apr 14, 2008 (MARKET WIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announces record sales/leases of ValiMed(TM) units in its 2nd fiscal quarter
ending April 30, 2008. "With the strong market demand and increasing number of
hospitals in our customer pipeline both domestically and internationally, we
have significantly increased the size of our current production run for ValiMed
units," said Tim Shriver, CDEX COO. "We have now ordered all of the major
components for 115 Units, allocated for both the national and international
markets."
The ValiMed Medication Validation System uses Enhanced Photoemission
Spectroscopy to quickly validate high-risk medication admixtures, as well as
returned narcotics, to provide an increased level of patient safety. ValiMed
compares a medication's spectroscopic signature to the expected signature from
the CDEX Medication Signature Library and returns an easy to understand
"validated" or "not validated" result, requiring no user interpretation.
"At the annual CDEX Shareholders Meeting, I emphasized that the 2008 goals for
ValiMed relate primarily to increased revenue, strengthening our internal
marketing arm, establishing strong international distribution channels in the
three primary regions of focus and expanding the ValiMed product line to offer
attractively priced products to all levels of the health care market," said
Malcolm Philips, CDEX CEO. "We are tracking well to these goals. We expect to
close the second quarter with ten new sales/leases of ValiMed units. CDEX
revenues increased approximately 80% from 2006 to 2007, and we believe will
substantially increase in 2008 based on our ValiMed product line alone, not
including sales from our Meth Scanner(TM) which we expect to begin next quarter.
We are pleased with this increasing number of ValiMed units in the field, which
translates into an increasing recurring revenue stream, such as from sale of our
patent pending cuvettes used with each ValiMed unit."
If Cdex keeps this up, the sales may shut the naysayers up. Although I doubt it!
Then the question is, what will the naysayers do if they can't complain about a stock they have no investment in?
News for 'CEXI' - (CDEX Inc. and GRIFOLS International SA Announce Business Partnership Relationship CDEX Inc. and GRIFOLS International SA to Enter Into Distribution Agreement for the ValiMed(TM) Medication Validation System in Southern Europe)
TUCSON, AZ and BARCELONA, SPAIN, Apr 09, 2008 (MARKET WIRE via COMTEX) -- CDEX
Inc. (OTCBB: CEXI) follows up on recent announcements regarding international
expansion by announcing today a business partnership agreement with GRIFOLS
International SA to distribute ValiMed(TM) in Spain, Portugal and Italy. The
ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to
quickly validate high-risk medication admixtures, as well as returned narcotics,
to provide an increased level of patient safety. ValiMed compares a medication's
spectroscopic signature to the expected signature from the CDEX Medication
Signature Library and returns an easy to understand "validated" or "not
validated" result, requiring no user interpretation.
"At Grifols we strive to provide hospitals with innovative products and services
that improve the quality, efficiency and effectiveness of patient care," said
Xavier Guix, Marketing Director at GRIFOLS International SA. "ValiMed integrates
well with that vision by bringing new and unique standards to enhance patient
medication safety. We are very excited about this new relationship with CDEX."
"We are very honored that a Company like Grifols, driven by high quality and
ethical standards is taking our products on board and we look forward to
developing a strong and long lasting relationship that will directly benefit our
customers in Southern Europe," said Malcolm Philips, CDEX President and CEO.
"Patient Medication Safety is a global concern and a top priority in all
hospitals. This announcement marks another concrete step in our goal of making
ValiMed a safety standard worldwide."
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is applying its resources in two distinct areas: (i)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed(TM) is a CDEX solution for the healthcare market. For more
information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm
Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppoulignyt@cdex-inc.com) at
520.745.5172 X 210.
About GRIFOLS International SA
Grifols is a holding company specialized in the pharmaceutical hospital sector
and present in more than 90 countries. Grifols has been present in healthcare
since 1940, creating innovative products and services based on the values of
ethics and responsibility. Grifols' activities focus on fulfilling the needs of
healthcare professionals working in therapeutics, pharmacy, diagnostics and
blood banking. For more than 60 years, Grifols has developed, manufactured and
marketed products designed to improve human health. The company manufactures
products of proven efficacy, quality and safety. More information about Grifols
can be found at http://www.grifols.com. Since 2006 the company is present on the
stock exchange as GRF.MC and was included on the prestigious IBEx-35 group of
companies in Spain starting on January 2008.
Sorry Crowe, most could care less what you think! We just don't care! CDEX will play itself out with or with out you.
Hospitals with Contracts for Purchase or Lease of one or more CDEX ValiMed™ Medication Validation Systems
(February 29, 2007)
All Children’s Hospital, Inc. (St. Petersburg, Florida)
Children’s Hospitals and Clinics of Minnesota (Minneapolis, Minnesota)
Children’s Hospitals and Clinics of Minnesota (St. Paul, Minnesota)
Children’s Medical Center of Dallas (Dallas Texas)
Cleveland Clinic Foundation (Cleveland, Ohio)
Henry Ford Health System (Detroit, Michigan)
Loyola University Medical Center (Maywood, Illinois)
Mount Carmel Health System (Columbus, Ohio)
Primary Children’s Medical Center (Salt Lake City, Utah)
Stanford Hospitals and Clinics (Stanford, California)
U.C. Davis Health System (Sacramento, California)
University of Maryland Medical Center (Baltimore, Maryland)
University of Michigan Health System (Ann Arbor, Michigan)
University of Utah Hospitals and Clinics (Salt Lake City, Utah)
Veterans Administration Hospital (Palo Alto, California)
Children's Hospital of The King's Daughters (Norfolk, VA)
Bronson Methodist Hospital (Kalamazoo, MI)
East Jefferson General Hospital (Metairie, LA)
Hospitals with Contracts for Purchase or Lease of one or more CDEX ValiMed™ Medication Validation Systems
(February 29, 2007)
All Children’s Hospital, Inc. (St. Petersburg, Florida)
Children’s Hospitals and Clinics of Minnesota (Minneapolis, Minnesota)
Children’s Hospitals and Clinics of Minnesota (St. Paul, Minnesota)
Children’s Medical Center of Dallas (Dallas Texas)
Cleveland Clinic Foundation (Cleveland, Ohio)
Henry Ford Health System (Detroit, Michigan)
Loyola University Medical Center (Maywood, Illinois)
Mount Carmel Health System (Columbus, Ohio)
Primary Children’s Medical Center (Salt Lake City, Utah)
Stanford Hospitals and Clinics (Stanford, California)
U.C. Davis Health System (Sacramento, California)
University of Maryland Medical Center (Baltimore, Maryland)
University of Michigan Health System (Ann Arbor, Michigan)
University of Utah Hospitals and Clinics (Salt Lake City, Utah)
Veterans Administration Hospital (Palo Alto, California)
Children's Hospital of The King's Daughters (Norfolk, VA)
Bronson Methodist Hospital (Kalamazoo, MI)
East Jefferson General Hospital (Metairie, LA)
Repeating yourself again? Over and over and over. The same story everyday? I think I saw that in some kind of a handbook.
ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES. The always negative crew will post this over and over again.
Why are you so worried that Cdex will make it?
CDEX already in production cycle for 200 Meth Scanners and they expect delivery of the first Scanners to a waiting client base during the 2nd Quarter 2008
http://www.marketwire.com/mw/release.do?id=837438